JPH0240045B2 - - Google Patents
Info
- Publication number
- JPH0240045B2 JPH0240045B2 JP58221728A JP22172883A JPH0240045B2 JP H0240045 B2 JPH0240045 B2 JP H0240045B2 JP 58221728 A JP58221728 A JP 58221728A JP 22172883 A JP22172883 A JP 22172883A JP H0240045 B2 JPH0240045 B2 JP H0240045B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- citric acid
- therapeutic agent
- papain
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 23
- 108090000526 Papain Proteins 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 10
- 229940055729 papain Drugs 0.000 claims description 10
- 235000019834 papain Nutrition 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 208000019423 liver disease Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940031627 papain 50 mg Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
【発明の詳細な説明】
本発明は肝臓疾患治療効果を有する薬剤に関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a drug having therapeutic effects on liver diseases.
口、食道、胃、腸、十二指腸、膵臓、肝臓等に
発生する口内炎、胃潰瘍、十二指腸潰瘍、膵臓
炎、肝臓肥大、肝炎、胆石症等は消化器系疾病と
いうことができる。 Stomatitis, gastric ulcer, duodenal ulcer, pancreatitis, liver hypertrophy, hepatitis, cholelithiasis, etc. that occur in the mouth, esophagus, stomach, intestines, duodenum, pancreas, liver, etc. can be considered digestive system diseases.
これらの消化器系疾病に対して食餌療法、薬の
投与等が行われているが満足できるものでないの
が現状である。 Dietary therapy, drug administration, etc. are being used to treat these digestive system diseases, but the results are not satisfactory at present.
本発明者は斯かる現状に鑑み、肝臓疾患に有用
な医薬について鉛意研究した結果、クエン酸に酵
素の一種であるパパインを併用した場合に、驚く
べきことに極めて迅速に且つ顕著に各種の肝臓疾
患の治療に有効であることを見い出した。 In view of the current situation, the present inventor conducted preliminary research on drugs useful for liver diseases, and found that when citric acid was used in combination with papain, which is a type of enzyme, various types of cancer were surprisingly rapidly and significantly cured. It was found to be effective in treating liver diseases.
例えば多くの人にこの薬を試したところ、肝臓
疾患に罹つていた人が、驚くべきことに服用後僅
か短期間で正常な状態になることが見い出され
た。 For example, when the drug was tested on many people, it was surprisingly found that those suffering from liver disease returned to normal after only a short period of time after taking it.
従来クエン酸単独を服用していた場合に比し、
クエン酸とパパインを併用して服用する場合、ク
エン酸独特の酸味が緩和され遥かに飲み易い。 Compared to conventionally taking citric acid alone,
When citric acid and papain are taken together, the sour taste unique to citric acid is alleviated, making it much easier to drink.
本発明はパパイン及びクエン酸を含有すること
を特徴とする肝臓疾患治療効果を有する薬剤に係
る。 The present invention relates to a drug containing papain and citric acid, which has a therapeutic effect on liver diseases.
本発明の薬剤は前記各種の肝臓疾患の治療に有
効である。 The drug of the present invention is effective in treating the various liver diseases mentioned above.
本発明の治療剤はクエン酸単独の場合に比し遥
かに飲み易く、またその効果が極めて短時間で発
現し、しかもその治療効果は医者が治療を断念し
た患者の場合にも治癒するという程に格別に顕著
である。また本発明の薬剤を摂取すると人や動物
の体臭、口臭が消失し、例えば排せつ物の特有の
臭いが消え、犬や猫に飲ますと、犬、猫に特有の
臭い及びその排せつ物の臭いが消失するという効
果も有している。 The therapeutic agent of the present invention is much easier to take than citric acid alone, and its effects appear in an extremely short period of time, and its therapeutic effects are such that even patients who have given up on treatment are cured by their doctors. This is especially noticeable. Furthermore, when the drug of the present invention is ingested, the body odor and bad breath of humans and animals disappear, for example, the characteristic odor of excrement disappears, and when taken by dogs and cats, the odor peculiar to dogs and cats and the odor of their excrement disappear. It also has the effect of
本発明で使用されるパパインは例えばパパヤの
果実等から採取される酵素で、通常粒末状または
顆粒状のものが有利に使用される。クエン酸も通
常市販のものを使用することができる。 The papain used in the present invention is an enzyme collected from, for example, papaya fruit, and is usually advantageously used in the form of powder or granules. Commercially available citric acid can also be used.
本発明の上記治療剤は種々の製剤化が可能であ
る。例えば経口投与剤として粉剤、錠剤、丸剤、
顆粒剤、水溶液、カプセル剤、懸濁剤、シロツプ
剤等、非経口投与剤として注射剤、坐剤等に製剤
できる。製剤に際して賦形剤としては公知の担体
を用いることができ、その他の添加剤として例え
ば充填剤、結合剤、滑沢剤、湿潤剤等を使用する
こともできる。本発明の治療剤は粉末のまま飲む
か、或いは水溶液として飲むのが特に有利であ
る。 The therapeutic agent of the present invention can be formulated into various formulations. For example, powders, tablets, pills,
It can be formulated into parenteral preparations such as granules, aqueous solutions, capsules, suspensions, syrups, etc., such as injections and suppositories. In formulation, known carriers can be used as excipients, and other additives such as fillers, binders, lubricants, wetting agents, etc. can also be used. It is particularly advantageous for the therapeutic agent of the invention to be taken as a powder or as an aqueous solution.
本発明の治療剤にはビタミンＣ等の各種のビタ
ミン類を添加することも有効である。 It is also effective to add various vitamins such as vitamin C to the therapeutic agent of the present invention.
本発明の治療剤中に含有される有効成分化合物
であるパパインとクエン酸の割合は広い範囲から
選定可能であるが、特に前者の１重量部に対して
後者を0.05〜20重量部、更には前者の１重量部に
対して後者を0.5〜５重量部使用するのが好まし
い。 The ratio of papain and citric acid, which are active ingredient compounds contained in the therapeutic agent of the present invention, can be selected from a wide range, but in particular, the ratio of the latter to 1 part by weight of the former is 0.05 to 20 parts by weight, or even It is preferable to use 0.5 to 5 parts by weight of the latter per 1 part by weight of the former.
本発明において治療剤中の有効成分の合計量は
特に限定されず広範囲に選定可能であるが、通常
は全組成物中約１〜100重量％、好ましくは約20
〜100重量％である。 In the present invention, the total amount of active ingredients in the therapeutic agent is not particularly limited and can be selected over a wide range, but is usually about 1 to 100% by weight, preferably about 20% by weight of the total composition.
~100% by weight.
本発明の治療剤の摂取量は、用法、患者の年
令、疾患の程度などにより適宜選択されるが、通
常有効成分を１日当り約50mg〜10ｇの範囲とする
のが好ましく、これを通常１日１〜10回程度に分
けて摂取するのが好ましい。 The intake amount of the therapeutic agent of the present invention is appropriately selected depending on the usage, age of the patient, degree of disease, etc., but it is usually preferable to keep the active ingredient in the range of about 50 mg to 10 g per day. It is preferable to take it divided into 1 to 10 times a day.
以下に本発明治療剤の製造例及び薬理効果につ
いて説明する。 Production examples and pharmacological effects of the therapeutic agent of the present invention will be explained below.
製造例 １
パパイン50mg及びクエン酸50mgを混合して本発
明の治療剤（粉剤）を得る。Production Example 1 A therapeutic agent (powder) of the present invention is obtained by mixing 50 mg of papain and 50 mg of citric acid.
製造例 ２
パパイン50mg、クエン酸100mg、デンプン200mg
を混合して本発明の治療剤（粉剤）を得る。Production example 2 papain 50mg, citric acid 100mg, starch 200mg
are mixed to obtain the therapeutic agent (powder) of the present invention.
製造例 ３
パパイン50mg及びクエン酸150mgを水100mlに溶
解して本発明の治療剤（水溶液）を得る。Production Example 3 A therapeutic agent (aqueous solution) of the present invention is obtained by dissolving 50 mg of papain and 150 mg of citric acid in 100 ml of water.
製造例 ４
パパイン100mg及びクエン酸50mgを水100mlに溶
解して本発明の治療剤（水溶液）を得る。Production Example 4 A therapeutic agent (aqueous solution) of the present invention is obtained by dissolving 100 mg of papain and 50 mg of citric acid in 100 ml of water.
１ 肝臓病治療効果
(1) 患者 S.N.50才、女
昭和40年、急性肝炎と黄だんで４ケ月入院
する。昭和50年、薬の副作用が原因でぼうこ
う炎となり１ケ月入院する。1 Effects of liver disease treatment (1) Patient SN, 50 years old, female In 1965, she was hospitalized for 4 months due to acute hepatitis and jaundice. In 1975, he developed cystitis due to side effects of medication and was hospitalized for a month.
昭和55年、肝臓の悪化により３ケ月入院す
る。その後、漢方薬を飲み大分良くなるが、
１ケ月に約３回程、疲れがひどく、お腹がは
る。 In 1981, he was hospitalized for three months due to deterioration of his liver. After that, I started drinking herbal medicine and felt much better, but
About 3 times a month, I feel extremely tired and have a bloated stomach.
昭和58年３月より本発明の治療剤を毎日摂
取したところ、約20日で体が楽になり、排尿
がきれいになり、お腹がはらなくなり、便秘
がなくなり、肩もこらなくなつた。 Starting in March 1982, he took the therapeutic agent of the present invention every day, and in about 20 days his body felt better, his urination became clearer, his stomach no longer bloated, he no longer had constipation, and his shoulders no longer felt stiff.
(2) 患者 Y.A.57才、女
昭和53年〜58年にかけて肝機能障害で３
回、入退院を繰り返す。 (2) Patient YA, 57 years old, female.
He was repeatedly hospitalized and hospitalized.
昭和58年、本発明の治療剤の服用を開始し
たところ、GOTが41、GPTが36となる。腹
水がとれ、食事がおいしくなり、ぐつすりと
寝ることができ、便秘がなくなり、風邪をひ
かなくなつた。 In 1981, when he started taking the therapeutic agent of the present invention, his GOT was 41 and his GPT was 36. My ascites went away, my food tasted better, I was able to sleep soundly, I no longer had constipation, and I no longer caught a cold.
比較試験データ
患者 T.K.55才、男
肝機能障害で体の調子が悪かつた。何も薬剤を
服用しないとこの状態が続いた。クエン酸を飲む
が胃が痛くなり続けることができなかつた。又、
パパインを飲むが効果はなかつた。Comparative test data Patient TK, 55 years old, male, was in poor physical condition due to liver dysfunction. This condition continued unless I took any medication. I drank citric acid, but I couldn't keep up with the pain in my stomach. or,
I took papain, but it had no effect.
Claims (1)
とする肝臓疾患治療効果を有する薬剤。1. A drug having a therapeutic effect on liver diseases characterized by containing papain and citric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58221728A JPS60112720A (en) | 1983-11-24 | 1983-11-24 | Drug, food and drink having remedying effect to disease of circulatory system and digestive system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58221728A JPS60112720A (en) | 1983-11-24 | 1983-11-24 | Drug, food and drink having remedying effect to disease of circulatory system and digestive system |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1005398A Division JPH01238539A (en) | 1989-01-12 | 1989-01-12 | Composition having remedying effect on dermatopathy |
| JP1276350A Division JPH02174655A (en) | 1989-10-23 | 1989-10-23 | Food and drink having treating effect on disease in digestive system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60112720A JPS60112720A (en) | 1985-06-19 |
| JPH0240045B2 true JPH0240045B2 (en) | 1990-09-10 |
Family
ID=16771323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58221728A Granted JPS60112720A (en) | 1983-11-24 | 1983-11-24 | Drug, food and drink having remedying effect to disease of circulatory system and digestive system |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60112720A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1001437B (en) * | 1992-11-05 | 1993-12-30 | Aggelos Kontos | Pastry system for the administration of pharmacologically active substances. |
| JPH06172209A (en) * | 1992-12-10 | 1994-06-21 | Reiko Kosaka | Composition for health of animal |
| GR1002668B (en) * | 1996-03-15 | 1997-04-14 | N | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt. |
| KR100932520B1 (en) * | 2002-10-31 | 2009-12-17 | 박래옥 | Anticancer agent composition |
-
1983
- 1983-11-24 JP JP58221728A patent/JPS60112720A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60112720A (en) | 1985-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Howard et al. | Drugs and breastfeeding | |
| JP5686615B2 (en) | A deep sleep disorder improving agent containing glycine | |
| Dock et al. | Cation exchangers: their use and hazards as aids in managing edema | |
| ES2236300T3 (en) | IRON COMPOSITIONS. | |
| US4477434A (en) | Medicinal compositions, foods and beverages having therapeutic effects on diseases of circulatory system and digestive system | |
| KR920003525B1 (en) | Magnesium additive for nutrients feed and medicaments | |
| DE3040780C2 (en) | Use of a pharmaceutical composition for the treatment of diabetes | |
| JPH0240045B2 (en) | ||
| JPH0340010B2 (en) | ||
| JPH05229938A (en) | Hypotensive agent | |
| JPH0638708A (en) | Sodium absorption inhibitor, sodium, absorption inhibitor-containing food for preventing hypertension and therapeutic agent for hypertension | |
| JP2002255801A (en) | Composition for prophylaxis of hypertension | |
| WO2006038613A1 (en) | Oral composition containing difructose anhydride | |
| TWI784169B (en) | Prevention or improvement agent for nocturnal frequent urination | |
| JP3793239B2 (en) | Inhibitor of acetaldehyde toxicity | |
| JP5634062B2 (en) | Composition for improving brain function and method for improving brain function | |
| WO2012036191A1 (en) | Composition for improving brain function and method for improving brain function | |
| JP2000514465A (en) | Use of PVP to reduce intestinal distention | |
| MacLeod | Dogs: homoeopathic remedies | |
| JP2002080376A (en) | Biologically active agent and medicine | |
| JP4655338B2 (en) | Drugs for improving iron deficiency anemia | |
| JP2579593B2 (en) | Health food containing calcium-containing composition excellent in absorbability, drug containing the composition | |
| RU2120280C1 (en) | Homeopathic agent "atsenamet" for treatment of alcohol addiction | |
| JPH06345660A (en) | Sodium absorption inhibitor, sodium absorption inhibiting food and drink and feed and drink for animal | |
| JPS64927B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |